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Non-alcoholic fatty liver disease (NAFLD), depo-
sition of fat in the liver due to causes other than
alcohol, includes non-alcoholic steatohepatitis
(NASH). NASH is a more severe form of NAFLD
in which fatty infiltration of the liver is accompa-
nied by necroinflammatory activity, and is now
recognized as one of the most common causes of
chronic liver disease. Given the increasing preva-
lence of obesity worldwide, the deleterious ef-
fects of NAFLD, and more particularly NASH, are
becoming of increasing concern for physicians.
Epidemiology
In 2003, it was estimated that the prevalence of
NAFLD ranged from 17% to 33% in the general
population of Western countries, and up to 80%
in the morbidly obese population.1 A study eval-
uating the prevalence of NASH estimated that
5.7–17% of the US population is affected.2 It is
reasonable to assume that these figures will con-
tinue to rise as the prevalence of obesity in the US
becomes increasingly common. Less information
is available on the prevalence of NASH beyond the
Western world. There have been a few studies eval-
uating the prevalence and significance of NASH
in East Asian populations. Chen et al evaluated a
cross-sectional study of adults in rural Taiwan and
found that the prevalence of NAFLD was 11.5%.
Risk factors with development of NAFLD identi-
fied in this population were male sex, elevated
alanine aminotransferase (ALT), obesity, elevated
fasting plasma glucose (> 126), elevated triglyc-
eride (> 150), and hyperuricemia.3 Yui and Leung
performed an epidemiologic study evaluating
Hong Kong Chinese adults for NAFLD using 
ultrasound criteria and found that the overall
prevalence of NAFLD in this population was
15.9%.4 Fan et al evaluated the prevalence of
NAFLD in the Shanghai adult male population
and found similar results, with 20.82% of the
population affected.5 Studies of the Korean pop-
ulation revealed similar results, with an age-
adjusted prevalence of 16%.6 See the Table for 
a comparison of the prevalence of NAFLD in var-
ious populations.3–7 Further studies are neces-
sary to evaluate the significance of NAFLD and
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the prevalence and significance of NASH in these
populations.
Natural History
The occurrence of NASH is clinically important
as approximately 15–25% of these patients will
progress to cirrhosis.8–10 Once cirrhosis is pres-
ent, it is estimated that 30–40% of these patients
will progress to a liver-related death over a 10-year
period.8–10 These figures confirm the need to
identify patients at risk, diagnose the presence of
NAFLD and NASH at earlier stages in the clinical
course, and intervene with patient education and
therapeutic options. It is important to note, how-
ever, that only a small percentage (approximately
20%) of patients who develop NAFLD will go on
to develop NASH.2
There is a clear correlation between NAFLD and
NASH with obesity. As mentioned above, studies
have shown that NAFLD is present in up to 80%
of the morbidly obese population.1 Additionally,
there is an association between NAFLD and 
the metabolic syndrome. Some researchers have
suggested that NAFLD, including NASH, may be
the liver manifestation of the metabolic syn-
drome. Studies have shown a correlation between
NAFLD and type 2 diabetes or impaired glucose
tolerance.11,12 This correlation may be important
for identifying patients who are at increased risk
of developing NAFLD including NASH.
Long-term data suggest that approximately 15–
25% of patients who develop NASH will progress
to develop liver cirrhosis.8–10 However, this figure
may be an underestimate. Several authors have
proposed that many patients who are diagnosed
with cryptogenic cirrhosis actually may have
NAFLD- and NASH-associated cirrhosis. But, there
is no evidence in the literature to suggest that pa-
tients with steatosis develop cirrhosis without first
progressing to NASH, although there are reported
cases of this phenomenon occurring in patients
with alcoholic liver disease.13
Pathophysiology
The development of non-alcoholic steatohepati-
tis is a complex process and is not completely
understood. It has been suggested that the devel-
opment of NASH is a two step process. The ini-
tial step involves deposition of fat in the liver
(NAFLD), likely as a result of insulin resistance
and increased fat mass. The second step involves
oxidative stress and oxidation of the fat in the
liver due to cytokine injury, hyperinsulinemia,
hepatic iron and/or lipid peroxidation (Figure).14
The development of insulin resistance is an in-
tricate process. In the setting of the metabolic
Table. Comparison of the prevalence of non-
alcoholic fatty liver disease in various
populations
Population Study size Prevalence
Rural Taiwan3 3245 11.5%*
Hong Kong Chinese4 1627 15.9%*
Shanghai males5 3175 20.8%*
Korea6 1613 16.0%*
US Caucasians7 731 33.0%†
US Hispanics7 400 45.0%†
US African-Americans7 1097 24.0%†
*Evidence for NAFLD based on ultrasound data; †evidence for
NAFLD based on proton magnetic resonance spectroscopy data.
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Figure. Scheme for the pathogenesis of steatosis and steatohepatitis.
syndrome, as is the case for many patients with
NASH, the increase in fat mass and adipocyte
differentiation plays a key role in the develop-
ment of insulin resistance. This is achieved mainly
by the adipocyte acting as an endocrine organ,
secreting adipokines, which have various local and
systemic responses. These include initiation of an
acute phase response, alterations of lipoprotein
metabolism, and energy homeostasis, variation
of the extracellular matrix, and changes in the
vasculature and immune system function.15 These
adipokines include tumor necrosis factor (TNF),
adiponectin, leptin, resistin, and angiotensin.
There have also been several studies evaluating
the actions of various adipokines in patients with
non-alcoholic steatohepatitis. It has been shown
that TNF is increased in patients who are obese
and have NAFLD.16 In the setting of the meta-
bolic syndrome involving the liver, the suspected
mechanism of TNF involves induction of hepatic
resistance to insulin via upregulation of the sup-
pressor of cytokine signaling proteins by decreas-
ing the ability of insulin to activate its signaling
pathway resistance.17–20 Additionally, adiponectin
has been found to play a key role in insulin sensi-
tivity,21 and low levels have been shown to pre-
cede and be predictive of the onset of type 2
diabetes mellitus.22 In NAFLD, adiponectin levels
were found to be decreased.23–25 Furthermore, it
has been found that exogenously administered
adiponectin in animal models of NAFLD improved
hepatic steatosis.26 With regards to angiotensin,
the renin-angiotensin system has been shown to
play a major role in the pathogenesis of hepatic
fibrosis.27,28 Early research has shown that angio-
tensin II antagonists may halt the progression 
of fibrosis in animal models,29 and may reverse
NAFLD-induced elevations of liver function tests
in humans.30
Insulin resistance ultimately results in hyper-
insulinemia with an increase in free fatty acid
(FFA) flux to the liver. Over a period of time, this
leads to the development of hepatic steatosis and
NAFLD. It is unclear why some patients who de-
velop NAFLD go on to develop NASH while others
do not. As mentioned above, it is suspected that
some type of oxidative stress is involved. There
are essentially four potential mechanisms that are
suspected to cause this oxidative stress. The first
mechanism is the production of proinflamma-
tory cytokines by Kupffer cells causing mitochon-
drial oxidative stress of hepatocytes, and ultimately
leading to necrosis and apoptosis. This pathway
was explored and detailed in animal models.31
The second proposed method of oxidative stress
development is through hyperinsulinemia itself.
It is thought that the key to insulin’s ability to
cause oxidative stress lies in its ability to upregu-
late the lipogenic protein, SREBP,32 as well as its
direct profibrogenic effects through stimulation
of connective tissue growth factor.33 The third
proposed mechanism is iron overload generating
reactive oxygen species and subsequent lipid per-
oxidation. Iron is known to have damaging 
effects on mitochondria,34 and approximately
30% of NAFLD patients do have elevated ferritin
levels.35,36 Additionally, phlebotomy has been
shown to improve liver histology in patients
with NAFLD.37 The last proposed mechanism of
oxidative stress in NASH involves lipid peroxida-
tion of FFAs. Patients with NAFLD have increased
delivery of FFAs to the liver38 where oxidation of
the FFAs produces hydrogen peroxide, superoxide
and lipid peroxides, all of which generate oxidative
stress.
Diagnosis
The gold standard for diagnosis of NAFLD in-
cluding NASH is the liver biopsy. The National
Institutes of Diabetes and Digestive and Kidney
Diseases (NIDDK)-sponsored NASH Clinical
Research Network (CRN) has developed a histo-
logical scoring system which is uniformly used
for all clinical trials involving NASH. Three dis-
tinct histologic lesions are necessary to make the
diagnosis of NASH. These are zone 3 macrosteato-
sis, hepatocyte ballooning and mixed lobular in-
flammation. There are other common findings on
liver biopsy in patients with NASH, including por-
tal inflammation, perisinusoidal zone 3 fibrosis,
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acidophil bodies, lipogranulomas, glycogenated
nuclei, periodic acid staining positive (after dia-
stase) Kupffer cells, Mallory’s hyaline, megamito-
chondria and mild siderosis.39 The severity of
disease is determined by the NAFLD activity score
(NAS) and the fibrosis score. These gradations are
useful for assessing change during clinical trials.
The major limitation of liver biopsy is sampling
variability, which may lead to misdiagnosis and
staging inaccuracies. Several studies have shown
sampling variability and uneven distribution of
histologic lesions of NASH during evaluation of
paired biopsies.40–42
Although liver biopsy is the current “gold stan-
dard” for diagnosis of NAFLD including NASH,
it is not a practical screening tool given the cost,
time-intensive nature and potential morbidity of
this procedure. Multiple modes of imaging can be
utilized to evaluate patients for NASH to varying
degrees of effectiveness. Ultrasound is a relatively
inexpensive form of liver imaging. Ultrasound
showing hyperechogenic liver tissue in contrast to
the spleen or kidney echogenicity is suggestive of
steatosis. However, the sensitivity of ultrasound
is only 60–94%.43 In addition, ultrasound is not
able to stage liver fibrosis. Unenhanced computed
tomography (CT) shows low liver attenuation in
steatosis, and the severity of steatosis correlates
with the liver-to-spleen attenuation ratio.44,45
The sensitivity of unenhanced CT is 93%, with a
76% positive predictive value in patients with
greater than 33% steatosis.46 Gradient-echo mag-
netic resonance imaging is also useful to evaluate
liver steatosis, with a sensitivity of 80% and
specificity of 71% in patients with at least 10%
steatosis.47
A current area of research is the development
of biomarkers to determine the extent of fibrosis.
Suzuki et al evaluated hyaluronic acid as a pre-
dictor of fibrosis in 79 patients, and found that it
was a reliable predictor in patients with grade
3–4 fibrosis (area under the curve, 0.90). However,
it was not sensitive for detecting mild fibrosis.48
Endothelin-1 is another mediator of hepatic fibro-
sis that has been evaluated as a predictor for fibro-
sis. Degertekin et al evaluated 40 patients with
biopsy-proven NASH and found that average 
endothelin-1 levels were significantly higher when
compared to patients with simple steatosis.49
Several diagnostic panels have been created
to predict fibrosis scores in patients using a vari-
ety of clinical data. The NAFLD fibrosis score is a
panel using age, body mass index, platelet count,
albumin, aspartate aminotransferase (AST)/ALT
ratio and hyperglycemia to predict fibrosis. It was
validated in two studies with 480 patients and
253 patients, respectively, and found to reliably
predict fibrosis with a negative predictive value
of 93% and 88%, and a positive predictive value
of 90% and 82%.50 A limitation of this panel is
that approximately 25% of patients are classified
as “indeterminate”. The Original European Liver
Fibrosis test is a panel utilizing similar markers 
to the NAFLD fibrosis score in addition to tissue
inhibitor of metalloproteinase 1 (TIMP 1), hyal-
uronic acid, and P3NP (procollagen-3 N-terminal
peptide). It was validated in a study with 196 pa-
tients, and found to have an area under the curve
of 0.98 for severe fibrosis, 0.93 for moderate fi-
brosis, and 0.84 for no fibrosis.51 The relative ac-
curacy of these two diagnostic panels suggests
that prediction of liver fibrosis is possible using a
series of markers. However, further studies with
larger sample sizes are needed to confirm their
accuracy.
Treatment
As mentioned above, obesity is one of the most
commonly associated comorbid conditions with
NASH. Several studies have suggested that
weight loss has beneficial effects on improve-
ment of, and potential reversal of NAFLD and
NASH. The majority of studies focused on im-
provements in liver biochemistry profiles in re-
sponse to weight loss. Palmer and Schaffner
demonstrated that a loss of at least 10% of body
mass in 39 obese patients was associated with 
reversal of abnormal liver function tests as well
as decreased hepatomegaly.52 A study of 25
obese Japanese patients showed improvement 
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in aminotransferases as well as total cholesterol
and fasting glucose levels in the subset of patients
who underwent a 3-month program of dietary
restriction and exercise.53 Knobler et al studied
48 patients who underwent dietary restriction
with resultant moderate weight loss (mean 3.7 kg
weight loss at 24-month follow-up) and found
that 96% of patients had improvement in liver
function tests and 50% had complete reversal of
previously elevated transaminases.54
Regarding pharmaceutical interventions, sev-
eral studies have investigated the effects of in-
sulin sensitizers on the improvement of NASH,
given the large percentage of patients with NASH
who have coexisting insulin resistance. Rosiglita-
zone (4 mg BID for 48 weeks) was shown to sig-
nificantly improve insulin sensitivity and serum
ALT levels in 25 patients with biopsy-proven
NASH, and repeat biopsy after 11 months of
treatment revealed histologic improvement in
necroinflammatory score in 45% of these patients.
Unfortunately, further follow-up at 6 months after
treatment cessation showed elevation of liver en-
zymes to near pretreatment levels.55 Pioglitazone
(30 mg daily for 48 weeks) has also been shown
to improve insulin sensitivity, serum ALT levels
as well as liver histology. A reduction in fibrosis
score on liver biopsy after 48 weeks of therapy was
seen in 51% of patients in this study. Interest-
ingly, follow-up data in patients 48 weeks after
stopping therapy showed a significant increase in
serum ALT, and worsening of all histologic find-
ings except fibrosis score to pretreatment val-
ues.56 A second study by Belfort et al confirmed
these findings. Fifty-five patients with biopsy-
confirmed NASH were randomized and given pi-
oglitazone (45 mg daily) versus placebo along
with a hypocaloric diet. The pioglitazone group
was found to have a significantly higher level of
normalization of serum aminotransferase levels,
decreased hepatic fat content, and improvement
of histologic findings.57 Some major drawbacks
to the use of the above thiazolidinediones are the
potential risk of hepatotoxicity and their con-
traindication for use in patients with active liver
disease with serum ALT levels more than 2.5 times
the upper limit. There have been two reports of
hepatic dysfunction associated with troglitazone.
Gitlin et al reported two patients with underly-
ing diabetes and obesity, but no known baseline
liver disease who developed severe hepatotox-
icity after troglitazone therapy.58 Watkins and
Whitcomb reviewed all clinical trials involving
troglitazone, and found that of the 2510 patients
involved in studies, 1.9% developed elevations
in serum ALT concentrations to greater than
three times the normal limit.59
Metformin has also been widely studied in
the setting of NASH. A study evaluating the effect
of metformin (850 mg BID for 24 weeks) in 36
patients with biopsy-proven NASH showed that
insulin sensitivity, and serum ALT and AST im-
proved significantly in the treatment group.
However, histologic evaluation in this study
failed to show significant improvement of necroin-
flammatory activity or fibrosis score.60 In a second
controlled study by Bugianesi et al, 55 patients
with NASH were given metformin (2 g daily for
48 weeks) and were found to have improvements
in serum ALT levels and decreased prevalence of
metabolic syndrome when compared to control
groups after 48 weeks of therapy. Histologic eval-
uation showed significant decreases in necroin-
flammation and fibrosis in the treatment group
after completion of 48 weeks of treatment. How-
ever, no biopsies were taken of the control group
for comparison.61
Attention has also been directed to the role of
antioxidants in the treatment of NASH, given the
proposed theory of its pathogenesis. A small
study by Hasegawa et al of 12 patients evaluated
the effect of vitamin E (300 mg/day for 1 year)
on transaminase levels and liver histology. Liver
biopsy following 1 year of treatment showed im-
provement in inflammation and fibrosis as well
as improvement in serum ALT levels.62 Other stud-
ies, however, have shown no beneficial effects.
Kugelmas et al evaluated the effects of vitamin E
(800 IU daily for 6 weeks) in a controlled study of
16 patients with biopsy-proven NASH, and found
no significant improvement in transaminase lev-
els.63 Larger randomized controlled studies are
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needed to further evaluate the effects of antioxi-
dants for this condition.
Ursodeoxycholic acid (UDCA) has also been
evaluated as a potential therapy for NASH. In a
smaller study by Lindor et al, 126 patients with
biopsy-proven NASH were randomized to re-
ceive between 13 and 15 mg/kg/day of UDCA for
2 years versus placebo. There were no significant
changes in the degree of steatosis, necroinflam-
mation, or fibrosis on repeat liver biopsy found
in the treatment group.64
The role of antihyperlipidemic agents in the
setting of NASH has also been analyzed in sev-
eral small studies. Gemfibrozil (600 mg daily for
4 weeks) was evaluated in 46 patients with
biopsy-proven NASH, and found to improve
serum ALT levels in patients after 4 weeks of
treatment when compared to a control group;
however, no histologic improvement was seen
on repeat liver biopsy.65 A small study of six pa-
tients evaluating clofibrate (2 g daily for 12
months) versus control group found that clofi-
brate did not improve ALT levels or liver his-
tology on evaluation after 1 year of treatment.66
Statins have been shown to reduce ALT levels;67,68
but data are limited with this drug class given its
potential risk of hepatotoxicity. A small study of
five patients evaluated the effects of pravastatin
(20 mg daily for 6 months) and found improve-
ment of fibrosis scores in three of the five patients
after 6 months of treatment.68
Surgical options for weight loss are becoming
increasingly utilized in the US health care sys-
tem. Systematic reviews have shown that all pro-
cedures are able to achieve more than 50% loss
of excess weight.69–71 However, there are no ran-
domized controlled trials to evaluate the effects
of bariatric surgery on liver disease. There are sev-
eral case series, and observational studies that do
suggest improvement of steatosis and inflamma-
tion following surgically-induced weight loss.
Mattar et al evaluated 70 patients with paired
biopsies pre- and post-weight loss from gastric
bypass surgery. Patients were re-evaluated on av-
erage 15 months postoperatively. The mean ex-
cess body weight loss at the time of re-evaluation
was 59 ± 22%. They noted significant improve-
ment in liver steatosis, inflammation and fibrosis
scores upon repeat biopsy.72 Other smaller stud-
ies have confirmed these findings.73,74 Gastric
banding has also been shown in small studies to
improve NAFLD and NASH. An evaluation of
liver histology in 36 patients who underwent
gastric banding showed major improvements in
lobular steatosis, necroinflammatory changes
and fibrosis after surgically induced weight loss
(average weight loss, 34 kg).75
Conclusion
NASH is becoming an increasingly common dis-
ease process, currently affecting up to 17% of
Western populations.2 Given the potential compli-
cations of NASH, including cirrhosis, it is essential
to identify patients at risk and direct early interven-
tion. Currently, the gold standard for diagnosis is
the liver biopsy; however, other diagnostic tools,
including imaging and biomarkers, are being
evaluated. The optimal treatment for NASH is
weight loss and lifestyle modifications including
diet and exercise. Surgical procedures for weight
loss have also been shown to improve NASH.
Metformin has also been shown to be a relatively
safe pharmaceutical intervention to improve liver
histology. Data suggest that significant lasting
weight loss is the only therapeutic intervention
that can lead to longstanding resolution of NASH.
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